MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023 – Medical Marijuana Program Connection

BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced that it plans to share information on the Company and its product pipeline, including an update on recent positive phase 2 study results for MYMD-1 in sarcopenia, at the upcoming BioFuture 2023 Meeting. Chris Chapman, MD, president, director,

Source link

• SEO Powered Content & PR Distribution. Get Amplified Today.
• PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
• PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
• PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
• PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
• Source: https://mmpconnect.com/mymd-pharmaceuticals-to-present-updated-statistically-significant-phase-2-data-for-mymd-1-potential-tnf-%ce%b1-market-disrupter-at-biofuture-2023/?utm_source=rss&utm_medium=rss&utm_campaign=mymd-pharmaceuticals-to-present-updated-statistically-significant-phase-2-data-for-mymd-1-potential-tnf-%25ce%25b1-market-disrupter-at-biofuture-2023